![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Characterization of Maraviroc Resistance in Patients Failing Treatment with CCR5-Tropic Virus in MOTIVATE 1 and 2
|
|
|
Reported by Jules Levin
3rd International Workshop on Targeting HIV Entry
Washington, DC, USA, December 7-8, 2007
Julie Mori1, Marilyn Lewis1, Paul Simpson1, Jeannette Whitcomb2, Lynn McFadyen1, Phylinda Chan1 and Mike Westby1
1Pfizer Global Research and Development, Sandwich, UK; 2Monogram Biosciences, California, USA
Maraviroc Resistance: Author Summary of Clinical Findings
Adequate exposure to maraviroc combined with a lack of active drugs in a patients OBT were the most likely reasons for the development of maraviroc resistance and subsequent treatment failure in four patients failing maraviroc-based therapy with CCR5-tropic virus
--Maraviroc resistance was selected in those patients who had ≦1 active background drug in their treatment regimen
--Maraviroc exposure was at the low end of the optimal exposure distribution
![V3-1.gif](../images/121107/V3-1.gif)
![mvc-2.gif](../images/121107/mvc-2.gif)
![MVC-3.gif](../images/121107/MVC-3.gif)
![qd-4.gif](../images/121107/qd-4.gif)
![Motive-5.gif](../images/121107/Motive-5.gif)
![patient-6.gif](../images/121107/patient-6.gif)
![FTC-7.gif](../images/121107/FTC-7.gif)
![Sensi-8.gif](../images/121107/Sensi-8.gif)
![maravior-9.gif](../images/121107/maravior-9.gif)
![noEvidence-10.gif](../images/121107/noEvidence-10.gif)
![Failure-11.gif](../images/121107/Failure-11.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|